Article Details
Retrieved on: 2024-10-16 21:00:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... gene therapy has met its primary endpoint. The sham-controlled bridging study evaluated the company's AAV-GAD therapy over 26 weeks in 14 patients ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here